Clinical Trial Search

Primary: Primary Efficacy Endpoint: Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score From Baseline to Day 35 — -130.7; -159.7; -99.0…

Primary: Change From Baseline at Week 26 in Skin Globotriaosylceramide (GL-3) Score in Superficial Skin Capillary Endothelium: Number of Participants in Categories of Shift in…

Primary: Geometric Mean Titers (GMTs) of Influenza Antibodies Following Vaccination With Either a High-Dose Quadrivalent Influenza Vaccine or High-Dose Trivalent Influenza…

Primary: Area Under the Plasma Concentration-time Curve (AUC) From Time Zero (Pre-dose) Extrapolated to Infinity (AUC[0-inf]) for Plasma Gepotidacin — 15894.7; 19505.7; 25415.5…

Primary: Vancomycin Concentration in Fat — 6.0; 40.5 ug/g — p=0.001

Primary: Number of Participants With Immediate Unsolicited Adverse Events (AE) After Vaccination — 0; 0; 0 Participants

Primary: Sydney Resection Quotient (SRQ) — 9.3; 8.1; 12.3; 11.1 Ratio

Primary: Change in HbA1c — -1.7; -1.0; -1.5; -1.0 Percentage (%) of HbA1c — p=<.0001

Primary: Cocaine Use — 58.9; 71.57; 69.63; 121.25 Dollar amounts of cocaine use

Primary: Overall Survival (OS) — 20.37; 19.75 Months — p=0.6945

Primary: Plasma Concentration of Dalcetrapib Active Form — 285; 272; 294; 231 ng/mL

Primary: Number of Patients Able to Collect >=6 x 106 CD34+ Cells/kg in <= 2 Collections. — 11; 0; 14 Participants — p=0.90

Primary: Bone Mineral Density — -0.015; -0.008 grams/cm^2

Primary: Time-matched Mean Change From Baseline in Corrected QT Intervals Based on the Fridericia's Correction Fomulation (QTcF) — 3.9; 3.5; 1.6; -0.3 millisecond (msec)

Primary: PCO2 Level Outside of Desired Range (40-60 mmHg) — 9; 8 participants